CClinicalTrials.gg
CompletedNCT06206694Updated Jun 6, 2025

Serum YKL-40 Levels is Associated With Nutritional and Oxidative Status of Hemodialysis Patients

An observational study in Malnutrition and Oxidative Stress, sponsored by Tungs' Taichung Metroharbour Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Tungs' Taichung Metroharbour Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
226
Ages
20 Years and older
Sex
All
01

Study summary

Background

YKL-40 is a glycoprotein that had been reported to be associated with inflammation atherosclerosis and endothelial dysfunction. The objective is to explore the association of serum YKL-40 levels with nutrition status, inflammation, and body composition in a cohort of hemodialysis patients

Methods

We plan to recruit 400 prevalent HD patients. Their baseline serum YKL-40 levels, body anthropometry, the profile of insulin resistance, bioimpedance spectroscopy parameters, and nutritional indices will be measured.

Read the detailed description

Study Design and Patients

Patients This is a prospective observational study. The patients will be recruited from HD patients at dialysis units of Tungs Taichung Metroharbour Hospital, which is an outpatient facility. The study inclusion criteria of participants are those maintain on HD therapy for at least 3 months prior to enrollment and being in stable condition without co-morbidities such as heart failure, infection, cirrhosis, respiratory disease, nephrotic syndrome, malignancy, chronic liver disease, or severe inflammation. None of the patients are receiving surgical operations or hospitalized in recent 3 months. In this study, written informed consent will be obtained from all participants. The study protocol will be send to the institutional review board of Tungs Taichung Metroharbour Hospital for approval. The study will be registered to the ClinicalTrial. Gov. Registry and will fully adhered to the guidelines of the Declaration of Helsinki

Methodology

Laboratory measurements Blood samples will be collected before dialysis session. Serum biochemistry such as albumin, urea nitrogen, uric acid, creatinine, total cholesterol, triacylglycerol levels, total ion binding capacity (TIBC), 25-hydroxyvitamin D, hemoglobin, and white blood count are measured employing standard laboratory techniques with the use of an automatic analyzer. Serum prealbumin and high-sensitivity C-reactive protein (hs-CRP) are quantified by nephelometry. YKL-40 and interleukin-6 (IL-6) were quantified by a double-sided sandwich-type enzyme-linked immunosorbent assay (ELISA) kit (R\&D Systems ; Minneapolis, MN, USA).

Fasting glucose levels were measured, after overnight fast and classified according to the American Diabetes Association (ADA) standards [29]. In addition, the serum insulin level, and hemoglobin A1c level are measured. The assessment of insulin resistance is done using the HOMA-IR index [30]: HOMA - IR = fasting glucose (in mmol/l) × fasting insulin (in µU/ml) / 22.5 Serum insulin, vaspin, and adiponectin level is measured by a commercially available ELISA kit following the manufacturer's instructions. Markers of oxidative stress such as total antioxidant capacity [TAC]), serum advanced oxidation protein products (AOPP) and serum CML (a component of AGEs) will also be measured.

Evaluation of nutritional status and body composition

Anthropometric measures including body weight, body mass index (BMI), waist and hip circumference, mid-arm circumference, and the waist-hip ratio (WHR) will be obtained. BMI is determined by the standard formula and further categorized according to the Asia Pacific version of the WHO classification [31-32]. According to this system, BMI\<18 kg/m2 is underweight; 18 to 22.9 is normal weight; 23 to 24.9 is marginal overweight; 25 to 29.9 is overweight; and greater than 30 is obesity [27, 28]. Lastly, the conicity index at baseline is determined to quantify the degree of central obesity [33].

Patients' nutrition status is determined by their serum albumin and pre-albumin levels, Subjective Global Assessment (SGA) score, normalized protein nitrogen appearance (NPNA), and fat-free edema-free body mass (FEBM). The 4-item 7-point SGA scoring system is employed [34]. NPNA was calculated using the modifed Bergstrom's formula [35]. FEBM was calculated using the creatinine kinetic method following the Forbes and Brunining formula [36], and reported as a percentage of their ideal body weight.

We use the multi-frequency bio-impedance spectroscopy device (Body Composition Monitor, Fresenius Medical Care, Germany) as described previously [36, 37]. In this study, the data on lean tissue mass (LTM), adipose tissue mass (ATM), the volume of over-hydration (OH), and the extracellular-tointracellular volume (E: I) ratio will be analyzed.

Statistical analysis All variables were analysed using a Kolmogorov-Smirnov test to classify them as normally or non-normally distributed. Values are given as mean [standard deviation (SD)] or median (IQR). Univariate analysis is performed to examine the relationships between YKL-40 and other parameters employing Spearman's rank correlation coefficient. Multivariate analysis is performed for parameters showing significant differences. Potential confounding factors for increased YKL-40 are assessed using a multiple regression analysis model based on general variables, inflammatory markers and correlations with malnutrition (p\<0.10). Two-sided P values of \<0.05 are considered to be statistically significant in all analyses. All statistical analyses were performed with the SPSS 23.0 statistical package (SPSS, Chicago, IL, USA). A p-value \<0.05 is considered statistically significant.

02

Conditions studied

  • Malnutrition
  • Oxidative Stress

Browse trials for

Keywords

  • YKL-40
  • nutrition status
  • hemodialysis patients
  • inflammation
03

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients have to be at least 20-years-old and hemodialysis (HD) for at least 3 months.

Inclusion criteria

  • Both sexes aged 20 years or over
  • Received stable hemodialysis at least 3 months.
  • Written informed consent.

Exclusion criteria

Exclusion Criteria:

  • heart failure
  • infection
  • cirrhosis
  • respiratory disease
  • nephrotic syndrome
  • malignancy
  • chronic liver disease
  • severe inflammation
  • None of the patients are receiving surgical operations or hospitalized in recent 3 months.
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
226 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
05

What researchers measure

Primary outcomes

  1. Analysis of biomarkers of YKL40

    YKL40 is also reportedly useful as an inflammation marker in HD patients

    Time frame: 1 years

  2. Evaluation of nutritional status and body composition

    Malnutrition, with a prevalence between 40% and 75% in maintenance hemodialysis patients is the most important risk factor for morbidity, the quality of life, all-cause mortality and cardiovascular mortality.

    Time frame: 1 years

Secondary outcomes

  1. Analysis of biomarkers of IL-6

    The IL-6 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods

    Time frame: 1 years

  2. vaspin

    The vaspin was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods

    Time frame: 1 years

  3. insulin

    The insulin was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods

    Time frame: 1 years

  4. adiponectin

    The adiponectin was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods

    Time frame: 1 years

  5. total antioxidant capacity

    Total antioxidant capacityassay is useful to assay antioxidant levels in serum

    Time frame: 1 years

  6. AOPP

    The IL-6 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods

    Time frame: 1 years

  7. Nε-Carboxymethyllysine (CML)

    The Nε-Carboxymethyllysine (CML) was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods

    Time frame: 1 years

06

Study locations

1 site
  • Tungs' Taichung MetroHarbour Hospital
    Taichung, Taiwan
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06206694
Lead sponsor
Tungs' Taichung Metroharbour Hospital
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
May 2, 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Jun 6, 2025

Study contacts

Paik Seong Lim, PhD
principal investigator · Tungs' Taichung Metroharbour Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion